Shire, AbbVie unveil $54 billion merger
U.S. drugmaker AbbVie has announced plans to takeover Dublin-based pharmaceutical company Shire in a deal worth around £32 billion ($54.7 billion), as AbbVie seeks to lower its tax rate by buying a foreign rival.
The Shire board has backed an offer that will be made up of £24.44 in cash and 0.8960 AbbVie share per Shire share, meaning AbbVie will pay about £52.48 per share for the specialist pharmaceutical firm.
Read More Planning a UK takeover? There are some pitfalls
Shire shareholders will end up owning 25 percent of the new merged group.
AbbVie said it expects the deal will cut its effective tax rate to approximately 13 percent.
Read More What new GSK cancer deal shows about pharma market
Shire shares were up as much as 2.5 percent shortly after the deal was announced.
If the takeover is successful, North Chicago-based AbbVie plans to relocate the new combined firm in the U.K., allowing it to benefit from the country’s lower tax.
Read More Why AbbVie’s UK bid may get easier ride than Pfizer
Shire is the second FTSE-listed pharmaceutical firm that has been approached by a U.S. rival, after Pfizer’s failed takeover bid for U.K. group Astra Zeneca.
The Shire Board, has been advised by Citi, Deutsche Bank, Evercore, Goldman Sachs and Morgan Stanley. Shire said the banks consider the terms of the transaction to be fair and reasonable.